Latest Breaking News On - J nephrol renovasc - Page 1 : comparemela.com

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi). The results showed a significant reduction of albuminuria, a marker of kidney damage,2 by up to 39.5% when BI 690517 was given on top of empagliflozin, a sodium glucose .

Rheinland pfalzUnited statesCarinne brouillonKatherine tuttleJ nephrol renovascColl cardiolKidney research instituteOxford population healthAmerican society of nephrologyBoehringer ingelheimAnimal healthNephrology divisionUniversity of washingtonAmerican societyKidney weekPrincipal study investigator

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibitor,.

United statesPrnewswire boehringer ingelheimColl cardiolJ nephrol renovascKatherine tuttleCarinne brouillonBoehringer ingelheim pharmaceuticals incKidney research instituteNephrology divisionAnimal healthAmerican society of nephrologyBoehringer ingelheimOxford population healthUniversity of washingtonOxford populationAmerican society

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKatherine tuttleColl cardiolCarinne brouillonJ nephrol renovascNlet alPrnewswire boehringer ingelheimAnimal healthKidney research instituteUniversity of washingtonOxford population healthNephrology divisionBoehringer ingelheimBoehringer ingelheim pharmaceuticals incAmerican society of nephrologyOxford population

EQS-News: SphingoTec GmbH: Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

EQS-News: SphingoTec GmbH: Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South koreaKangwon doRepublic of koreaSphingotec gmbJ nephrol renovascRuxandra lenzEui yul choiSphingotec gmbhBoditech med incAgreement strategic company decisionDistribution servicesStrategic company decisionMarket development agreementBoost commercializationKidney function biomarker penkidBoditech med

Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
nashvilleherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nashvilleherald.com Daily Mail and Mail on Sunday newspapers.

South koreaKangwon doRepublic of koreaSphingotec gmbh hennigsdorfEui yul choiJ nephrol renovascSphingotec gmbhSphingotec gmbBoditech med incBoditech medYul choiKidney injuryDiagnostic approachesClin biochemEarly biomarkerSeptic acute kidney injury